TCMD · Insider Trading
Tactile Systems Technology, Inc.
Every open-market purchase and sale reported by TCMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Sheri Louise Dodd | Chief Executive Officer | Sell | −10,978 | −$323.24K |
| 2026-05-13 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | Sell | −4,631 | −$113.40K |
| 2026-05-08 | Laura G. King | Director | A | +6,521 | — |
| 2026-05-08 | Carmen B Volkart | Director | A | +6,521 | — |
| 2026-05-08 | Raymond Huggenberger | Director | A | +6,521 | — |
| 2026-05-08 | Valerie L. Asbury | Director | A | +6,521 | — |
| 2026-05-08 | William W Burke | Director | A | +6,521 | — |
| 2026-05-08 | Andrea Pearson | Director | A | +6,521 | — |
| 2026-05-08 | David Brent Shafer | Director | A | +6,521 | — |
| 2026-05-08 | Boyd Vindell Washington | Director | A | +6,521 | — |
| 2026-03-11 | Andrea Pearson | Director | A | +852 | — |
| 2026-02-26 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | Sell | −7,701 | −$222.88K |
| 2026-02-26 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | Sell | −6,246 | −$180.76K |
| 2026-02-26 | Sheri Louise Dodd | Chief Executive Officer | Sell | −10,993 | −$318.14K |
| 2026-02-24 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | MIXED | +20,401 | −$156.14K |
| 2026-02-24 | Sheri Louise Dodd | Chief Executive Officer | MIXED | +32,727 | −$431.25K |
| 2026-02-24 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | MIXED | +10,232 | −$125.61K |
| 2026-02-23 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | A | +6,194 | — |
| 2026-02-23 | Sheri Louise Dodd | Chief Executive Officer | A | +48,672 | — |
| 2026-02-23 | Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | A | +23,008 | — |
| 2026-01-06 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | Sell | −5,139 | −$148.26K |
| 2025-08-12 | Sheri Louise Dodd | Chief Executive Officer | Sell | −7,762 | −$95.91K |
| 2025-05-14 | Elaine M. Birkemeyer | Chief Financial Officer | Sell | −2,921 | −$29.04K |
| 2025-05-12 | Sheri Louise Dodd | Chief Executive Officer | Sell | −3,149 | −$30.95K |
| 2025-05-09 | Valerie L. Asbury | Director | A | +16,078 | — |
| 2025-05-09 | Laura G. King | Director | A | +16,078 | — |
| 2025-05-09 | Carmen B Volkart | Director | A | +16,078 | — |
| 2025-05-09 | David Brent Shafer | Director | A | +16,078 | — |
| 2025-05-09 | William W Burke | Director | MIXED | +12,778 | −$31.91K |
| 2025-05-09 | Raymond Huggenberger | Director | A | +16,078 | — |
| 2025-05-09 | Boyd Vindell Washington | Director | A | +16,078 | — |
| 2025-03-13 | Daniel L. Reuvers | Director | G | — | — |
| 2025-02-27 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | Sell | −6,468 | −$93.16K |
| 2025-02-27 | Daniel L. Reuvers | Director | Sell | −28,338 | −$401.85K |
| 2025-02-27 | Elaine M. Birkemeyer | Chief Financial Officer | Sell | −2,066 | −$29.98K |
| 2025-02-24 | Elaine M. Birkemeyer | Chief Financial Officer | MIXED | +42,803 | −$55.54K |
| 2025-02-24 | Laura G. King | Director | A | +2,970 | — |
| 2025-02-24 | Sheri Louise Dodd | Chief Executive Officer | A | +85,777 | — |
| 2025-02-24 | Daniel L. Reuvers | Director | MIXED | +4,915 | −$159.15K |
| 2025-02-24 | Kristie Burns | Sr. VP Mktg & Clinical Affairs | MIXED | +19,239 | −$70.75K |
| 2024-08-14 | Sherri Lee Ferstler | Senior VP, Sales | Sell | −1,550 | −$20.26K |
| 2024-08-09 | Sheri Louise Dodd | Chief Executive Officer | A | +64,959 | — |
| 2024-05-20 | Elaine M. Birkemeyer | Chief Financial Officer | Sell | −3,041 | −$41.59K |
| 2024-05-10 | David Brent Shafer | Director | A | +10,469 | — |
| 2024-05-10 | Valerie L. Asbury | Director | A | +10,469 | — |
| 2024-05-10 | Sheri Louise Dodd | Director | A | +10,469 | — |
| 2024-05-10 | Boyd Vindell Washington | Director | A | +10,469 | — |
| 2024-05-10 | Raymond Huggenberger | Director | A | +10,469 | — |
| 2024-05-10 | William W Burke | Director | MIXED | +7,969 | −$35.15K |
| 2024-05-10 | Carmen B Volkart | Director | A | +10,469 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sheri Louise Dodd | Chief Executive Officer | 232,907 | $5.15M |
| Daniel L. Reuvers | President and CEO | 214,604 | $4.75M |
| Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | 130,188 | $2.88M |
| Kristie Burns | Sr. VP Mktg & Clinical Affairs | 82,581 | $1.83M |
| Raymond Huggenberger | Director | 62,841 | $1.39M |
| David Brent Shafer | Director | 55,343 | $1.22M |
| Valerie L. Asbury | Director | 55,343 | $1.22M |
| William W Burke | Director | 55,041 | $1.22M |
| Carmen B Volkart | Director | 44,219 | $978.12K |
| Boyd Vindell Washington | Director | 41,768 | $923.91K |
| Laura G. King | Director | 25,569 | $565.59K |
| Andrea Pearson | Director | 7,373 | $163.09K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TCMD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.